Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

camizestrant (AZD9833)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

Selective estrogen receptor degrader

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	AZD9833 Sensitive: C3 – Early Trials AZD9833 Sensitive : C3	AZD9833 Sensitive: C3 – Early Trials AZD9833 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	capivasertib + AZD9833 Sensitive: C3 – Early Trials capivasertib + AZD9833 Sensitive : C3	capivasertib + AZD9833 Sensitive: C3 – Early Trials capivasertib + AZD9833 Sensitive : C3
ER D538G	Estrogen Receptor Positive Breast Cancer	ER D538G	Estrogen Receptor Positive Breast Cancer	AZD9833 Sensitive: D – Preclinical AZD9833 Sensitive : D	AZD9833 Sensitive: D – Preclinical AZD9833 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D